

Review

An Emerging Role for isomiRs and the microRNA Epitranscriptome in Neovascularization

Reginald V.C.T. van der Kwast¹, Paul H.A. Quax¹  and A. Yaël Nossent^{1,2,*}

¹ Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; rvdkwast@lumc.nl (R.V.C.T.v.d.K.); P.H.A.Quax@lumc.nl (P.H.A.Q.)

² Department of Laboratory Medicine and Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria

* Correspondence: a.y.nossent@lumc.nl

Received: 29 November 2019; Accepted: 21 December 2019; Published: 25 December 2019



Abstract: Therapeutic neovascularization can facilitate blood flow recovery in patients with ischemic cardiovascular disease, the leading cause of death worldwide. Neovascularization encompasses both angiogenesis, the sprouting of new capillaries from existing vessels, and arteriogenesis, the maturation of preexisting collateral arterioles into fully functional arteries. Both angiogenesis and arteriogenesis are highly multifactorial processes that require a multifactorial regulator to be stimulated simultaneously. MicroRNAs can regulate both angiogenesis and arteriogenesis due to their ability to modulate expression of many genes simultaneously. Recent studies have revealed that many microRNAs have variants with altered terminal sequences, known as isomiRs. Additionally, endogenous microRNAs have been identified that carry biochemically modified nucleotides, revealing a dynamic microRNA epitranscriptome. Both types of microRNA alterations were shown to be dynamically regulated in response to ischemia and are able to influence neovascularization by affecting the microRNA's biogenesis, or even its silencing activity. Therefore, these novel regulatory layers influence microRNA functioning and could provide new opportunities to stimulate neovascularization. In this review we will highlight the formation and function of isomiRs and various forms of microRNA modifications, and discuss recent findings that demonstrate that both isomiRs and microRNA modifications directly affect neovascularization and vascular remodeling.

Keywords: microRNA; isomiRs; epitranscriptome; neovascularization; angiogenesis; arteriogenesis; A-to-I editing; m6A; RNA modifications; RNA methylation

1. Introduction

Ischemic cardiovascular disease (CVD) is the leading cause of death in worldwide and was responsible for approximately 17.8 million deaths in 2017 [1,2]. Additionally, it is estimated that current standard therapies are unsuitable or insufficient for 30% of patients [3,4]. Therefore, there is a critical need for new therapeutic treatments for ischemic CVD.

A potential strategy to treat patients with ischemia is to stimulate neovascularization, which is the body's natural repair mechanism to restore blood flow to ischemic tissues. Postnatal neovascularization is comprised of angiogenesis, the sprouting of new capillaries from existing vessels, and arteriogenesis, the maturation of preexisting collateral arterioles into fully functional arteries. Both angiogenesis and arteriogenesis are highly multifactorial processes that involve multiple types of vascular and immune cells. In order to improve neovascularization as a whole, therapeutic strategies which simultaneously target both angiogenesis and arteriogenesis are needed [5,6].

During the last decade, microRNAs have emerged as multifactorial regulators of neovascularization [7–9]. MicroRNAs are short non-coding RNAs of approximately 22 nucleotides that inhibit translation of messenger RNAs (mRNAs). A single microRNA can have hundreds of mRNAs in its ‘targetome’, often regulating an entire network or pathway simultaneously [10]. MicroRNAs are typically defined as one specific sequence of RNA nucleotides, however, recent studies have shown that this ‘canonical’ microRNA sequence is often altered. These microRNA alterations can be grouped into two types: (i) isomiRs, which are microRNAs with altered terminal sequences and (ii) biochemical modifications of specific nucleotides within microRNAs, which collectively are referred to as the microRNA epitranscriptome. Both types of microRNA variations appear actively regulated in response to ischemia and can directly influence neovascularization associated processes, as we will discuss below. The microRNA epitranscriptome unveils a whole new regulatory layer that could provide novel therapeutic options for ischemic CVD. In this review we will first briefly introduce the processes involved in angiogenesis and arteriogenesis, after which we will highlight various ways in which a microRNA can be altered, and discuss recent findings which demonstrate that these microRNA alterations can affect neovascularization associated processes.

2. Neovascularization—Angiogenesis and Arteriogenesis

After the occlusion of a large artery, blood flow to the downstream tissues is hampered, causing ischemia. Blood flow towards the ischemic tissue can be restored by a process called arteriogenesis. Arteriogenesis is the growth and maturation of collateral arteries from a pre-existing arteriole network, which connects all major arteries in the body [5]. Arteriogenesis is triggered by an increase in shear stress in the arterioles, which occurs after an arterial occlusion causes redirection of blood flow through the arterioles. The increased shear stress causes endothelial cells (ECs) in the arteriole wall to express adhesion molecules and secrete cytokines, leading to the attraction of circulating monocytes and other immune cells [11–15]. These inflammatory cells produce and secrete proteases, growth factors, and cytokines which enable remodeling of the vessel wall and stimulate migration and proliferation of vascular ECs and smooth muscle cells (SMCs) [16–18]. This results in an increase in vessel diameter, until fluid shear stress decreases which halts the arteriogenic process. Finally, the vascular SMCs and fibroblasts secrete matrix components to reconstitute the vessel wall [19,20].

The process of angiogenesis, on the other hand, is the sprouting of a new capillary from the existing vasculature in order to redistribute local blood flow towards ischemic areas. Unlike arteriogenesis, angiogenesis is driven by the hypoxia caused by ischemia, and revolves around resolving local ischemia rather than restoring arterial blood flow after the occlusion of a vessel. Angiogenesis is initiated when an angiogenic stimulus, produced by hypoxic cells, activates the vascular endothelial layer. Activated ECs will start to proliferate and migrate towards the stimulus, such as vascular endothelial growth factor (VEGF), resulting in a new capillary [21]. Next to ECs, other cell types are important regulators of angiogenesis. Vascular SMCs, pericytes, fibroblasts and immune cells play key roles by supporting and modulating EC function and secreting the proangiogenic stimuli to start the process [22–24].

Since both angiogenesis and arteriogenesis are highly multifactorial processes, the simultaneous stimulation of both processes requires a multifactorial regulator, like microRNAs [7,8].

3. MicroRNAs

MicroRNAs are endogenous, small non-coding RNA molecules that inhibit translation of mRNAs. The microRNA’s target selection is predominantly determined by the microRNA’s ‘seed sequence’, nucleotides 2–8 at the 5’-end of a microRNA [25,26], which bind their target mRNAs via Watson–Crick base-pairing. Due to this relatively small targeting sequence, a single microRNA’s ‘targetome’ can consist of hundreds of mRNAs, enabling microRNAs to regulate multifactorial processes [10].

The biogenesis of microRNAs starts with the transcription of the microRNA containing gene, yielding a primary microRNA (pri-miR) which then undergoes several steps of maturation to form the mature and functional microRNA (Figure 1) [27]. First, the pri-miR is cleaved in the nucleus by Drosha

to generate a hairpin-shaped precursor microRNA (pre-miR) [28]. The pre-miR is then translocated to the cytoplasm where a final cleavage is performed by Dicer, yielding a microRNA duplex [29]. Either side of the duplex can associate with Argonaute proteins and become a functional mature microRNA after incorporation into the RNA-induced silencing complex (RISC) [30]. Mature microRNAs are named after their side, 5' or 3', in the pri-miR hairpin (e.g., miR-#-5p or -3p).




Figure 1. MicroRNA biogenesis and alterations that induce isomiR formation or microRNA nucleotide modifications. Transcription of the microRNA containing gene forms the primary microRNA (pri-miR). Drosha cleaves the pri-miR to generate the precursor microRNA (pre-miR). The pre-miR cleaved by Dicer in the cytoplasm yielding the microRNA duplex. Either side of the duplex can be incorporated into the RNA-induced silencing complex (RISC) to become a functional mature microRNA. IsomiRs can be formed during microRNA biogenesis when Drosha or Dicer cleave in alternative locations, or when exonucleases or nucleotidyl transferases remove or add nucleotides to the 3'-end of the pre-miR or the mature microRNA. RNA nucleotide modifications with known or potential functional implications on microRNA biogenesis or functioning are shown in red with their 'writers' next to them.

MicroRNA biogenesis is strictly regulated, even at a microRNA-specific level, by numerous factors, including DNA methylation, activity modulation of key maturation proteins and many RNA-binding proteins [29,31–33]. As a result, microRNA expression is often highly tissue specific and is dynamically regulated during key physiological processes, including the response to ischemia [29,34].

In 2007, the importance of microRNAs in neovascularization was demonstrated for the first time when several studies showed that Dicer-dependent microRNAs were required for angiogenesis [35–37]. Since then, microRNAs have been shown to play a functional role in all processes involved in neovascularization, including production and secretion of angiogenic stimuli, as well as EC, SMC, fibroblast and immune cell proliferation, migration and activation, which have recently been reviewed in references [8,38–40]. Several of these vasoactive microRNAs have also been well described to play an important role in vascular remodeling during ischemic cardiovascular diseases [8,41].

For example, Bonauer et al. showed that miR-92a is highly expressed in human ECs and functions as negative regulator of angiogenesis [42]. Inhibition of miR-92a increased angiogenesis in vivo and improved blood flow recovery after hindlimb ischemia [42]. Furthermore, administration of miR-92a inhibitors in porcine models for myocardial infarction demonstrated that miR-92 inhibition prevents adverse infarct remodeling and ischemia/reperfusion injury [43,44]. Phase 1 trials aimed to improve

wound healing with a future potential clinical application towards heart failure treatment have recently been completed for miR-92a inhibitor MRG 110 (NCT03603431) [45].

Both miR-126-3p and -5p are also highly expressed in ECs where they promote angiogenesis by stimulating EC proliferation and VEGF signaling and regulating leukocyte adhesion [46–49]. Inhibition of miR-126-3p was shown to decrease recovery after myocardial infarction and hindlimb ischemia in mice [47,50,51]. Furthermore, miR-126 levels are decreased in patients with ischemic coronary artery disease [52]. Similarly, miR-10a also stimulates angiogenesis by promoting VEGF signaling in ECs and regulating their inflammatory phenotype [53–57].

MiR-21-5p regulates proliferation and apoptosis of vascular wall smooth muscle cells [58,59] and promotes fibrosis by stimulating fibroblast survival and growth factor secretion [60]. Preclinical studies have shown that inhibition of miR-21-5p can prevent maladaptive vascular remodeling and heart failure [59,60]. These findings suggest that the miR-21-5p inhibitor RG-012, which is currently being tested in a phase 2 clinical trial to prevent kidney fibrosis in patients with Alport syndrome (NCT02855268), could potentially be used for the treatment of CVD.

Additionally, it is noteworthy that several groups of genomically clustered microRNAs have been identified that are able to broadly regulate neovascularization in response to ischemia: Knockout of the miR-17/92 gene cluster (located on chromosome 14 in mice and on human chromosome 13) increased both angiogenesis and arteriogenesis [61,62], while the inhibition of individual microRNAs from the 14q32 microRNA cluster (located on chromosome 12F1 in mice and on human chromosome 14) was shown to independently stimulate both angiogenesis and arteriogenesis [9].

4. IsomiRs and the microRNA Epitranscriptome

Typically, microRNAs have been defined as a single sequence of RNA nucleotides, and are listed as such in the principle public microRNA database, miRbase [63]. However, recent studies have shown that this ‘canonical’ microRNA sequence can be altered. These microRNA alterations can be separated into two types: isomiRs and RNA nucleotide modifications.

IsomiRs are microRNA sequence variants that have one or more nucleotides added or deleted at their 5'- and/or 3'-ends compared to the canonical microRNA sequence.

RNA nucleotide modifications are biochemical modifications of the standard RNA nucleotides, which are performed by enzymes present in all living organisms. Recent studies have demonstrated that these RNA nucleotide modifications have a functional regulatory role and form what has been named the ‘epitranscriptome’ [64]. While many different RNA nucleotide modifications exist, only a few have been studied in the context of microRNAs: Adenosine-to-inosine editing (A-to-I editing) and N6-adenosine methylation (m6A) and 2'-O-methylation (2'OMe).

Below, we will discuss those studies that demonstrate that isomiRs and microRNA A-to-I editing and m6A can be actively regulated and play a directing role in neovascularization, as well as other modifications (including 2'OMe) that are likely to have a similar role.

5. IsomiRs

5.1. IsomiRs

IsomiRs were discovered when microRNA sequencing studies observed that many microRNAs had sequence variants with one or more nucleotides added or deleted from the 5'- and/or 3'-ends compared to the ‘canonical’ microRNA sequence [65,66]. While initially dismissed as errors or artifacts, isomiRs have since been shown to be functional microRNAs which actively associate with the RISC complex and inhibit mRNA translation of their targets [67–70]. Furthermore, sequencing studies have shown that isomiRs are widespread and represent approximately 50% of the microRNA transcripts present in cells and tissue [71,72].

IsomiRs are primarily generated by cleavage variations of either DROSHA or DICER during microRNA biogenesis (Figure 1) [68,73]. IsomiRs with altered 3'-end sequences, 3'-isomiRs, can also be

created by exonucleases which remove 3' nucleotides, or by nucleotidyl transferases, which catalyze the addition of 3' nucleotides. The number and type of isomiRs that arise from a single locus varies per microRNA, but approximately 75% of microRNA loci give rise to at least one isomiR [74].

In general, 3'-isomiRs are more abundant than 5'-isomiRs, however, a number of microRNAs do have prevalent 5'-isomiRs [75–78]. Since a microRNA's 5'-end determines its seed sequence, 5'-isomiRs have an altered targetome compared to the canonical microRNA sequence and are thus functionally different (Figure 2) [67,79–81]. While 3'-isomiRs do not have an altered seed sequence, their 3'-end variability has been associated with altered microRNA stability and turnover [82–86]. Furthermore, recent findings have shown that changes in microRNA length due to 3'-end variation can affect microRNA targeting strength and activity in specific cases [87,88]. Combined, these findings highlight the importance to take isomiRs into account during microRNA research.

pri-miR-21 sequence	CGGGUAGCUUAUCAGACUGAUGUUGACUGU	Mechanisms of formation	Potential effects
canonical miR-21-5p	5' <u>UAGCUUAUCAGACUGAUGUUGA</u> 3'	<ul style="list-style-type: none"> canonical biogenesis 	<ul style="list-style-type: none"> canonical function
5'-isomiRs	<u>AGCUUAUCAGACUGAUGUUGA</u> GUAGCUUAUCAGACUGAUGUUGA	<ul style="list-style-type: none"> alternative cleavage by Dicer or Drosha 	<ul style="list-style-type: none"> altered targetome length-dependent effects
3'-isomiRs	UAGCUUAUCAGACUGAUGUUGAC UAGCUUAUCAGACUGAUG UAGCUUAUCAGACUGAUGUUGA	<ul style="list-style-type: none"> alternative cleavage by Dicer or Drosha exonuclease or nucleotidyl transferase activity 	<ul style="list-style-type: none"> altered stability and/or turnover length-dependent effects
5' & 3'-isomiRs	AGCUUAUCAGACUGAUGUUGAC UAGCUUAUCAGACUGAUGUUGA AGCUUAUCAGACUGAUGUUGA	<ul style="list-style-type: none"> alternative cleavage by Dicer and/or Drosha exonuclease or nucleotidyl transferase activity 	<ul style="list-style-type: none"> altered targetome altered stability and/or turnover length-dependent effects

Figure 2. Different types of isomiRs, their mechanism of formation and their potential functional effects. The sequence of miR-21 and some of its isomiRs are shown to exemplify the different isomiR types. In each case, the seed sequence is underlined (red if altered) and red nucleotides are due to nucleotidyl transferase activity. Relative to the canonical microRNA, 5'-isomiRs generally have an altered targetome due to shift in seed sequence whereas 3'-isomiRs can affect the microRNAs stability or turnover. Both types of isomiRs affect the length of the microRNA and can thus incur length-dependent effects.

5.2. IsomiRs in Neovascularization Associated Cells and Processes

Due to the prevalence of isomiRs, most microRNAs that are known regulators of neovascularization have isomiRs. In fact, the microRNA loci with the most known isomiRs are miR-21-5p (Figure 2) and miR-10a-5p, two microRNAs with well-established roles in vascular biology and neovascularization [53–57], which have at least 40 isomiRs each [74]. MiR-21-5p isomiRs were found to be highly expressed in endothelial cells, as well as, miR-126-5p and -3p and their isomiRs, which are also well-established vasoactive microRNAs [8,89–91]. Combined, the miR-21-5p and miR-126 transcripts accounted for almost 40% of the total endothelial microRNA transcripts detected, including at least two 5'-isomiRs with physiologically relevant abundance [89,91]. One of these studies reported that approximately 55% of the total microRNA transcripts detected in human umbilical vein endothelial cells (HUVECs) were in fact isomiRs originating from 230 distinct microRNA loci [89]. For 33 of these microRNA loci, the isomiR variant was the most abundant form, rather than the canonical sequence. Since isomiRs often have altered stability and turnover [83–86], these abundant isomiRs could help regulate vasoactive microRNA expression. Furthermore, abundant 5'-isomiRs are likely to be functionally important due to their altered seed sequence and thus targetome.

IsomiR expression profiles can vary based on cell type and in response to biological stimuli, including stimuli associated with neovascularization [75,76,78,92]. For example, Voellenke et al. examined isomiR expression of normoxic and hypoxic human umbilical vein endothelial cells (HUVECs) using deep sequencing [89]. While the study lacked the power to identify any statistically significant patterns, the authors did observe that hypoxic conditions altered isomiR expression. Furthermore, Nejad et al. demonstrated that treating fibroblasts with interferon-beta, a regulatory factor in both angiogenesis and arteriogenesis [93–95], specifically decreased expression of the longer 3'-isomiRs from 13 microRNA loci, while the shorter isomiRs were generally upregulated [96]. Among the regulated microRNAs was

miR-222-3p, which has been shown to regulate angiogenesis and inflammation-mediated vascular remodeling [97,98]. Interestingly, the longer 3'-isomiRs of miR-222-3p (>22 nt) were previously found to increase apoptotic activity, whereas the shorter isomiRs did not, suggesting the altered 3'-isomiR profiles could also be functionally important [88]. However, the exact factors that mediate the isomiR-specific regulation remain to be uncovered. It is likely that, similar to canonical microRNA biogenesis, isomiR biogenesis is regulated by a multitude of factors, including factors which specifically regulate individual isomiRs [29,31,68].

We have recently performed a focused study on the 5'-isomiR of miR-411-5p from the vasoactive 14q32 microRNA cluster in order to collect direct evidence that isomiRs are actively regulated during ischemia-induced neovascularization [99]. We found that miR-411's isomiR expression profile was tissue-specific and that canonical miR-411-5p was less abundant than its 5'-isomiR in human vascular ECs, fibroblasts and in whole human venous tissue. We discovered that the expression of the 5'-isomiR is decreased relative to canonical miR-411-5p expression in response to acute ischemia, both in cells and in a murine model for effective neovascularization after ischemia [99]. Strikingly, the relative 5'-isomiR expression was upregulated instead in ischemic veins from patients with critical limb ischemia due to peripheral artery disease (PAD). We demonstrated that the 5'-isomiR has a different targetome than the canonical miR-411-5p and inhibits translation of, among others, the pro-angiogenic Angiopoietin-1. Finally, we showed that the 5'-isomiR decreases vascular cell migration while the canonical miR-411-5p does not [99]. Combined these data show that isomiR formation is indeed a functional pathway, which is actively regulated during ischemia, with direct implications for neovascularization.

Table 1 presents a summary of the key studies that demonstrate the prevalence and importance of isomiRs.

Table 1. Key studies demonstrating the prevalence and importance of isomiRs.

Topic	Key Findings	References
Prevalence of isomiRs	<ul style="list-style-type: none"> Generally, isomiRs represent ~50% of microRNA transcripts in cells and tissues (~55% in HUVECs) ~75% of microRNA loci can produce at least 1 isomiR 	<p>[71,72,89,91]</p> <p>[74]</p>
Potential functional effect of isomiRs	<ul style="list-style-type: none"> 5'-isomiRs have altered targetome due to a shifted seed sequence compared to the canonical microRNA 3'-isomiRs can have altered microRNA stability and turnover isomiRs with different length can have altered targeting strength and activity 	<p>[67,79–81,99]</p> <p>[82–86]</p> <p>[87,88]</p>
Abundant vasoactive microRNAs with isomiRs	<ul style="list-style-type: none"> miR-21-5p (at least 43 potential isomiRs, also in HUVECs) miR-10a-5p (at least 41 isomiRs) miR-126 (highly abundant in HUVECs together with miR-21-5p and its isomiRs) miR-222-3p (has functionally different 3'-isomiRs) miR-411-5p (5'-isomiR has altered functionality and anti-angiogenic properties) 	<p>[74,89,91]</p> <p>[74]</p> <p>[89,91]</p> <p>[88,96]</p> <p>[99]</p>
Regulation of isomiRs	<ul style="list-style-type: none"> IsomiR expression profiles can vary based on cell type and in response to biological stimuli Hypoxic HUVECs display altered isomiR expression Independent regulation of miR-411-5p and its 5'-isomiR in response to ischemia 	<p>[75,76,78,92]</p> <p>[89]</p> <p>[99]</p>

HUVECs: human umbilical vein endothelial cells.

6. Adenosine-to-Inosine Editing

6.1. Adenosine-to-Inosine Editing

A-to-I editing is the biochemical modification of adenosines into inosines by deamination. Unlike adenosine, inosine preferentially binds to cytidine and is therefore generally interpreted

as guanosine by the cellular machinery [100]. This form of RNA editing can have a number of consequences on RNA functioning, ranging from destabilizing the RNA molecules' secondary structure to altering a protein amino acid sequence due to editing of the mRNA's coding sequence [101–103]. In mammals, A-to-I editing accounts for more than 90% of all RNA editing events and is catalyzed by either ADAR1 or ADAR2 (adenosine deaminase acting on RNA 1 or 2), which are expressed throughout the body [104–106]. The removal of the editing activity of either ADAR1 or ADAR2 in mice leads to premature lethality, demonstrating that A-to-I editing is of vital importance [107–109]. However, the precise regulatory mechanisms governing this critical cellular process have yet to be fully elucidated [110]. Changes to ADAR levels or its activity were shown to affect global editing, but these observations do not always correlate well with frequencies of individual editing events [111,112]. Therefore, it is evident that additional regulatory mechanisms exist that modulate A-to-I editing in a site-specific manner.

ADARs specifically target double stranded RNA structures, including those found in pri-miRs (Figure 1). The editing of a pri-miR can profoundly influence microRNA maturation, resulting in changes in mature microRNA expression [113–115]. However, when editing alters the microRNA's seed sequence, this can completely change the mature microRNA's target selection, resulting in the regulation of a different targetome [116].

6.2. MicroRNA A-to-I Editing in Neovascularization

MicroRNA editing is a widespread phenomenon which also affects many vasoactive microRNAs, as demonstrated recently in a study by Li et al. The authors mapped microRNA A-to-I editing at an unprecedented scale and found 2711 potential pri-miR editing sites within approximately 80% of all human pri-miRs [117]. MicroRNA editing profiles were also found to be tissue-specific, which is in agreement with previous findings [113,115,118]. Furthermore, 367 potential editing sites were found within human mature microRNAs, often located in the seed sequence [117].

In the field of cancer research, several microRNA editing events were shown to have a functional effect on cell migration and/or proliferation [119–121], which are also crucial processes in both angiogenesis and arteriogenesis [20,21]. For example, seed sequence editing of miR-455-5p was shown to alter its targetome, causing edited miR-455-5p to decrease tumor cell proliferation and migration, while the unedited version had the opposite effect [122]. Furthermore, editing of the seed sequence of miR-200b enhanced tumor cell proliferation and migration, in contrast to the unedited version [120]. Interestingly, higher miR-200b editing levels were associated with a poorer prognosis in cancer patients, highlighting the possibility that microRNA editing can be clinically relevant as a biomarker or therapeutic target.

We have recently demonstrated that microRNA-editing can also directly regulate neovascularization. We showed that A-to-I-editing of miR-487b-3p, another microRNA from the vasoactive 14q32 microRNA cluster, is increased in ischemic muscle tissues undergoing neovascularization after induction of hindlimb ischemia [123]. MiR-487b-3p editing was also found in all human vascular ECs, SMCs, and fibroblasts. The edited mature miR-487b-3p has a unique targetome and promotes angiogenesis, in contrast to the canonical miR-487b-3p [123]. In a follow-up study, we demonstrate that vasoactive microRNA editing is a widespread phenomenon that enhances neovascularization in response to ischemia (manuscript submitted).

7. N6-Adenosine Methylation

7.1. N6-Adenosine Methylation

The modification of adenosine to N⁶-methyladenosine (m6A) is perhaps the most prevalent RNA nucleotide modification in eukaryotic cells and is present in more than 25% of human transcripts [124,125]. m6A is installed by the methyltransferase complex containing 'writer' METTL3 (Methyltransferase Like 3) and RNA-binding platform METTL14 [126], supported by cofactors WTAP

(Wilms' tumor 1-associating protein) and KIAA1429 [127,128]. Strikingly, m6A levels are dynamically regulated throughout all stages of life, with the help of m6A demethylases, or 'erasers', FTO (fat mass and obesity-associated protein), and ALKBH5 (alkB homolog 5) [129,130]. m6A methylation has been shown to affect almost every aspect of RNA metabolism, from expression and processing in the nucleus to translation and degradation in the cytoplasm [131–133]. The importance of its functions is illustrated by studies that demonstrate that individual knockout of either METTL3, METTL14 or WTAP causes prenatal lethality in mice [134–136]. While m6A can alter RNA folding and structure [137,138], most of m6A's biological functions are mediated through a group of 'reader' proteins that specifically recognize the methylated adenosine on RNA, including the YTHD (YT521-B homology domain) and the IGF2BP (insulin-like growth factor-2 mRNA-binding protein) families [127,139–141].

While most m6A research has focused predominantly on mRNAs, several studies have demonstrated that m6A is important for microRNA biogenesis. Alarcon et al. demonstrated that pri-miRs are marked by the METTL3-dependent m6A (Figure 1). Pri-miR m6A marks are read by m6A-binding protein hnRNPA2B1 that, in turn, stimulates initiation of DICER-mediated processing through recruitment of DICER's cofactor DGCR8 [142,143]. Intriguingly, a study by Berulava et al. demonstrated that well over 200 mature microRNAs contain m6A in a human embryonic kidney cell line (HEK293). While m6A does not affect canonical base pairing, several studies have suggested that it may block the noncanonical A:G base pairing, which could affect mRNA-microRNA interaction strength [138,144]. This is supported by a recent study that found that an m6A modified miR-200c-3p resulted in significantly less suppression of its target genes than unmethylated miR-200c-3p [145]. Furthermore, recent studies also suggest that m6A of mRNAs can influence their 'targetability' by microRNAs by promoting or preventing the binding of certain RNA-binding proteins that block microRNA-mediated transcript destabilization [141,146].

7.2. Importance of m6A in the Cardio-Vasculature and in Vasoactive MicroRNAs

Two recent studies have demonstrated the importance of m6A in cardiovascular homeostasis. Dorn et al. demonstrates that METTL3-dependant m6A helps modulate cardiac homeostasis and hypertrophic stress responses in mice [147]. The overexpression of METTL3 was shown to cause spontaneous hypertrophy, whereas METTL3 knockdown leads to maladaptive remodeling and signs of heart failure. Mathiyalagan et al. demonstrated that m6A is increased in failing mammalian hearts and in hypoxic cardiomyocytes [148]. Furthermore, increasing the expression of m6A eraser FTO in ischemic mouse hearts attenuates the ischemia-induced increase in m6A and decrease in cardiac contractile function. These findings highlight a key role for m6A in ischemic cardiovascular disease.

Pri-miR m6A marks were shown to be required for the appropriate processing of most pri-miRs to mature miRNAs, including vasoactive microRNAs [142,143]. Furthermore, m6A of the above mentioned vasoactive miR-126 and miR-222 was shown to affect cell migration and/or proliferation in cancer cells. A study by Ma et al., demonstrated that the pri-miR of miR-126 undergoes METTL14-dependent m6A, which facilitates its processing to mature miR-126 [149]. Decreased METTL14-dependent m6A of pri-miR-126 led to the reduced expression of miR-126, which in turn increased cancer cell migration and invasion [149]. Han et al. showed that METTL3-dependant m6A of pri-miR-222 increases its maturation to mature miR-222, resulting in the reduction of PTEN, and ultimately leading to the proliferation of bladder cancer [150]. Furthermore, METTL3 was increased in bladder cancer and correlated with poor patient prognosis [150].

Combined, the abundance of m6A, its importance in microRNA biogenesis and functioning, and the dysregulation of m6A during ischemia and cardiovascular disease, suggest that m6A of microRNAs could play an important role in ischemic cardiovascular disease and neovascularization.

8. Other Modifications in the microRNA Epitranscriptome

As mentioned above, numerous other RNA nucleotide modifications exist, however, their presence and function in small RNAs (16–28 nucleotides long), which consist mostly of microRNAs [151],

remains understudied [152]. An important reason for this is that conventional methods to detect RNA modifications are often unsuitable for small RNAs [152,153]. Recently, Lan et al. optimized a screening based on mass spectrometry which allowed them to provide the first overview of RNA nucleotide modifications in mammalian small RNAs using human HEK293T cells [154]. Besides inosine and m6A, 22 additional distinct nucleotide modifications were found, 13 of which consisted of different types or combinations of RNA methylations [154]. While little is known about the effect of these RNA nucleotide modifications on the functioning of small RNA, and thus microRNA, several have been studied in other RNA types.

Below, we will report the key findings of these studied RNA modifications and highlight which properties could potentially affect microRNA function. Furthermore, the discussed nucleotide modifications and their potential effects on microRNAs are summarized in Table 2.

Table 2. Known or postulated effects of nucleotide modification within microRNAs.

Nucleotide Modification	Abbreviation	Writers	Erasers	Potential Effects on microRNAs
Adenosine-to-inosine editing	A-to-I editing	ADAR1 or ADAR2	-	<ul style="list-style-type: none"> • pri-miR editing can profoundly influence maturation • seed sequence editing can alter targetome
N6-methyl-adenosine	m6A	METTL3/14	ALKBH5 FTO	<ul style="list-style-type: none"> • regulates pri-miR processing • hampered nonstandard A:G base pairing may affect silencing activity
Pseudouridine	Ψ	PUSs	-	<ul style="list-style-type: none"> • stronger base pairing with adenosine might affect silencing activity *
2'-O-methyl-nucleosides	2'OMe	Methyl-transferases	-	<ul style="list-style-type: none"> • may protect from A-to-I editing * • may affect stability and turnover * • enhanced RNA-RNA duplex stability might affect silencing activity *
N1-methyl-adenosine	m1A	TRMT6 & 61	ALKBH3	<ul style="list-style-type: none"> • positive charge can dramatically alter interactions with proteins * • disrupts RNA base pairing which can affect silencing activity *
N5-methyl-cytosine	m5C	NSUNs DNMT2	-	<ul style="list-style-type: none"> • may enhance stability *
N2-methyl-guanosine	m2G	unclear	-	<ul style="list-style-type: none"> • allows noncanonical base pairing which may affect silencing activity *

* effects are postulated effects based on observations in other RNA types.

8.1. Pseudouridine (Ψ)

Pseudouridine (Ψ) is one of the most abundant RNA modifications [155,156]. Ψ is highly conserved and is generated from isomerization of uridine, catalyzed by pseudouridine synthases (PUSs) [155,156]. Recent advances in high-resolution detection methods have demonstrated that Ψ-nucleotides are found in many, if not all, species of RNA [156,157]. Pseudouridylation was shown to be important for ribosomal RNA biogenesis, pre-mRNA splicing, and translation fidelity [155,156]. Compared to a uracil, Ψ forms a stronger base pairing interaction with adenosine, which allows it to alter RNA secondary structures, suggesting that microRNA pseudouridylation could affect mRNA silencing [158,159]. Furthermore, transcriptome wide pseudouridylation was shown to increase under stress conditions, including serum deprivation, a key component of ischemia [160].

8.2. 2'-O-Methylnucleosides

It is known that 2'-O-methylation (2'OMe) can reside on all four ribonucleosides and is widely conserved [161,162]. Furthermore, 2'OMe is performed by methyltransferases like Fibrillarlin and many, if not all, 2'OMe-events are directed by small nucleolar RNAs [64,163,164]. 2'OMe appears essential in processing ribosomal RNAs, small nuclear RNAs, and transfer RNAs, but it has also been found in mRNAs and even in microRNAs, by our group among others [123,161,165]. While the precise location and function of 2'OMe sites in many RNA types are currently unclear, 2'OMe in general has a stabilizing effect and can influence interactions with proteins or other RNAs [161,162]. 2'OMe may in fact protect adenosine residues from A-to-I editing [165–167]. Interestingly, we found that both 2'OMe and A-to-I editing of the same adenosine residue in pri-miR-487b are increased simultaneously under ischemia [123]. However, further studies are required to examine whether both RNA modifications can be found on a single copy of miR-487b-3p. Finally, 2'OMe also greatly enhances the stability of RNA-RNA duplexes, a quality that is often utilized to enhance the stability and specificity of synthetic antisense RNA-oligonucleotides, with similar implications for 2'OMe of microRNAs [168–171].

8.3. N1-Methyladenosine (m1A)

Recent methodological advances have demonstrated that m1A is a transcriptome-wide modification [172,173]. Several members of the TRMT family (tRNA methyltransferase family) have already been shown to be m1A writers and additional writers are thought to exist [172–174]. Similar to m6A, m1A is reversible and can be demethylated by erasers ALKBH1 and 3 (alkB homolog 1 and 3) [173,175]. Furthermore, m1A levels are dynamically regulated by various types of cellular stress and correlate with upregulation of translation in general [172,173]. This modification carries a positive charge and can therefore alter both protein–RNA interactions and RNA secondary structures dramatically [131], which can potentially lead to disruption of microRNA biogenesis [29]. Furthermore, m1A appears to disrupts RNA base-pairing and induces local RNA duplex melting, suggesting that m1A may also affect microRNA-target interactions [132,176].

8.4. N5-Methylcytosine (m5C)

While best known as a DNA modification in the epigenome, m5C can be installed on RNAs too by members from the NSUN family (nucleolar protein/sun RNA methyltransferase family) and by DNMT2 (DNA methyltransferase-2) and is therefore also part of the epitranscriptome [177–181]. m5C has been found in both noncoding and coding RNAs in mammals and a few studies have shown that m5C has functional implications [177,182,183]. For example, m5C of tRNAs was shown to protect tRNAs against stress-induced cleavage [180,184,185]. Furthermore, the depletion of m5C methyltransferase Nsun7 in mice resulted in a concomitant decrease of expression of specific non-coding RNAs, suggesting m5C marks can enhance RNA stability [186].

8.5. N2-Methylguanosine (m2G)

In tRNAs and rRNAs, m2G is a relatively common RNA modification, however, which m2G writers are responsible in humans remains unclear [187,188]. Interestingly, the study by Lan et al. demonstrated that m2G is also relatively common in small RNAs [154]. Our knowledge about this RNA modification is still very limited due to a lack of high-throughput detection methods [188,189]. However, studies have shown that m2G can form both canonical and non-canonical Watson–Crick base pairing interactions, allowing m2G to regulate the stability of tRNA tertiary structures and potentially influence microRNA silencing activity [188,190].

9. Dynamic Regulation of the Epitranscriptome

The epitranscriptome is dynamically regulated. This is abundantly clear for m6A modifications due to the discovery of both m6A writers and erasers [147,148]. Not all modifications may be reversible

like m6A, but most, if not all, other modifications do appear to be regulated. Several studies have shown that RNA alterations are modulated under stress and pathological conditions [64,191,192]. For example, the deposition and distribution of m6A were increased in response to heat shock and DNA damage [193–195]. Total transcriptomic pseudouridylation increased in response to heat shock, nutrient deprivation, and serum deprivation [157,160]. Further, m1A levels in mammalian cells also increased in response to heat shock, but decreased after nutrient starvation [172]. Furthermore, cellular m5C levels are decreased in response external stress and cytotoxic stress which affects protein translation rates [196,197]. Additionally, the expression of methyltransferase Fibrillarin is increased in many cancers to facilitate additional 2'OMe of ribosomal RNAs [162,198,199], while mRNA A-to-I editing is induced by both hypoxia and inflammation [200]. Importantly, we have shown that both A-to-I editing and 2'OMe also increase in microRNAs during ischemia [123,201]. These findings suggest that the microRNA epitranscriptome is likely to also be dynamically regulated and functional in pathological conditions, and could provide novel targets for therapeutic intervention.

Several studies have also indicated that certain RNA nucleotide modifications regulate each other. As mentioned previously, 2'OMe was found to protect adenosine residues from A-to-I editing [165–167]. A different study demonstrated that replacing an adenosine which can be A-to-I edited by m6A also prevents editing almost completely in an *in vitro* assay [202]. Furthermore, it was recently demonstrated that transcript m6A levels are negatively correlated with the A-to-I editing levels of the transcript, even when they are not competing for the same nucleotide [203]. The depletion of m6A resulted in upregulated A-to-I editing on the m6A-depleted transcripts, confirming a transcriptome wide interplay between m6A and A-to-I editing [203]. These findings highlight the complexity of the epitranscriptome and the importance of studying multiple RNA modifications simultaneously in order to examine known interactions and to identify novel interactions.

10. Concluding Remarks

During the past decade, both isomiRs and the epitranscriptome have emerged as novel and dynamic layers of regulation of gene expression. Both types of microRNA alterations have been shown to modulate key physiological responses, including neovascularization by affecting the microRNA's biogenesis, stability and function. MicroRNAs have already been established as multifactorial regulators of both angiogenesis and arteriogenesis [7–9], and therefore this additional regulatory layer may provide new options for therapeutic neovascularization. The therapeutic potential of both isomiRs and the microRNA epitranscriptome is highlighted by the findings that 5'-isomiR formation of miR-411-5p and A-to-I editing of miR-487b-3p are actively regulated in response to ischemia *in vivo*, resulting in novel microRNAs with anti- or pro-angiogenic properties, respectively [99,123]. Therefore, altered microRNAs could provide novel targets for therapeutic inhibition or overexpression to stimulate neovascularization after ischemic CVD.

The first therapeutic small RNA (Patisiran) was granted FDA approval in 2018 and the first phase 2 clinical trials with microRNA-oriented RNA therapeutics are currently ongoing, highlighting that microRNA therapeutics are on their way to clinical practice [45]. Over the last decade, important advances have been made in development of microRNA therapeutics, however, several key issues remain, which have been expertly reviewed in the studies by Lucas et al. and Rupaimoole et al. [41,204]. These issues include maximizing the effect of the therapeutics' effect on the diseased tissue, while minimizing the off-target binding and toxicity. Now that the prevalence and functionality of microRNA alterations are becoming clear, further research is warranted to understand which altered microRNAs could pose off-target risks during design and development of microRNA-based therapeutics. However, uncovering the intricate mechanisms which govern regulation of microRNA alterations could also reveal novel therapeutic targets to modulate microRNA functioning.

Alternatively, tissue- and pathology-specific regulation of the microRNA alterations could potentially be used as a biomarker for cardiovascular disease, considering that isomiR expression profiles were found sufficient to distinguish between cancer subtypes [205].

Finally, while the abundance and function of many nucleotide modifications have not been studied in microRNAs yet, it is likely that most, if not all, will prove clinically relevant. The unique properties of certain nucleotide modifications, like for example m6A, could be exploited to enhance the specificity of microRNA-therapeutics when targeting microRNAs carrying such modifications. It is important to note that further advances in technology and methodology are required to expand our knowledge of the microRNA epitranscriptome [154,206]. However, given the surge of interest in this field, we expect many more clinically relevant microRNA alteration events to be discovered in the near future.

Author Contributions: Conceptualization—R.V.C.T.v.d.K., P.H.A.Q. and A.Y.N.; Writing—Original Draft—R.V.C.T.v.d.K.; Writing—Review & Editing—R.V.C.T.v.d.K., P.H.A.Q. and A.Y.N.; Funding Acquisition—A.Y.N. All authors have read and agreed to the published version of the manuscript.

Funding: R.V.C.T.v.d.K. was supported by a grant from the Dutch Heart Foundation (E. Dekker Senior Postdoc Grant, A.Y.N., 2014T102). A.Y.N. was supported by the LUMC Johanna Zaaier Fund (2017) and the Austrian Science Fund FWF (Lise Meitner Grant, A.Y.N., M2578-B30).

Conflicts of Interest: The authors declare no conflict of interest

References

1. Timmis, A.; Townsend, N.; Gale, C.; Grobbee, R.; Maniadakis, N.; Flather, M.; Wilkins, E.; Wright, L.; Vos, R.; Bax, J.; et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. *Eur Heart J.* **2018**, *39*, 508–579. [[CrossRef](#)] [[PubMed](#)]
2. Kaptoge, S.; Pennells, L.; De Bacquer, D.; Cooney, M.T.; Kavousi, M.; Stevens, G.; Riley, L.M.; Savin, S.; Khan, T.; Altay, S.; et al. World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. *Lancet Glob. Health* **2019**, *7*, e1332–e1345. [[CrossRef](#)]
3. Dormandy, J.; Heeck, L.; Vig, S. Acute limb ischemia. *Semin. Vasc. Surg.* **1999**, *12*, 148–153. [[PubMed](#)]
4. Powell, R.J.; Comerota, A.J.; Berceci, S.A.; Guzman, R.; Henry, T.D.; Tzeng, E.; Velazquez, O.; Marston, W.A.; Bartel, R.L.; Longcore, A.; et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. *J. Vasc. Surg.* **2011**, *54*, 1032–1041. [[CrossRef](#)] [[PubMed](#)]
5. Van Oostrom, M.C.; van Oostrom, O.; Quax, P.H.; Verhaar, M.C.; Hoefer, I.E. Insights into mechanisms behind arteriogenesis: What does the future hold? *J. Leukoc. Biol.* **2008**, *84*, 1379–1391. [[CrossRef](#)] [[PubMed](#)]
6. Raval, Z.; Losordo, D.W. Cell Therapy of Peripheral Arterial Disease: From Experimental Findings to Clinical Trials. *Circ. Res.* **2013**, *112*, 1288–1302. [[CrossRef](#)]
7. Weber, C. MicroRNAs: From basic mechanisms to clinical application in cardiovascular medicine. *Arterioscler. Thromb. Vasc. Biol.* **2013**, *33*, 168–169. [[CrossRef](#)]
8. Welten, S.M.; Goossens, E.A.; Quax, P.H.; Nossent, A.Y. The multifactorial nature of microRNAs in vascular remodelling. *Cardiovasc. Res.* **2016**, *110*, 6–22. [[CrossRef](#)]
9. Welten, S.M.; Bastiaansen, A.J.; de Jong, R.C.; de Vries, M.R.; Peters, E.H.; Boonstra, M.; Sheikh, S.P.; La, M.N.; Kandimalla, E.R.; Quax, P.H.; et al. Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494 and miR-495 Increases Neovascularization and Blood Flow Recovery after Ischemia. *Circ. Res.* **2014**, *115*, 696–708. [[CrossRef](#)]
10. Friedman, R.C.; Farh, K.K.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* **2009**, *19*, 92–105. [[CrossRef](#)]
11. Heil, M.; Schaper, W. Pathophysiology of collateral development. *Coron. Artery Dis.* **2004**, *15*, 373–378. [[CrossRef](#)] [[PubMed](#)]
12. Hoefer, I.E.; van Royen, N.; Rectenwald, J.E.; Deindl, E.; Hua, J.; Jost, M.; Grundmann, S.; Voskuil, M.; Ozaki, C.K.; Piek, J.J.; et al. Arteriogenesis proceeds via ICAM-1/Mac-1-mediated mechanisms. *Circ. Res.* **2004**, *94*, 1179–1185. [[CrossRef](#)] [[PubMed](#)]
13. Scholz, D.; Ito, W.; Fleming, I.; Deindl, E.; Sauer, A.; Wiesnet, M.; Busse, R.; Schaper, J.; Schaper, W. Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). *Virchows Arch.* **2000**, *436*, 257–270. [[CrossRef](#)] [[PubMed](#)]

14. Hoefler, I.E.; van Royen, N.; Rectenwald, J.E.; Bray, E.J.; Abouhamze, Z.; Moldawer, L.L.; Voskuil, M.; Piek, J.J.; Buschmann, I.R.; Ozaki, C.K. Direct evidence for tumor necrosis factor- α signaling in arteriogenesis. *Circulation* **2002**, *105*, 1639–1641. [[CrossRef](#)] [[PubMed](#)]
15. Kosaki, K.; Ando, J.; Korenaga, R.; Kurokawa, T.; Kamiya, A. Fluid shear stress increases the production of granulocyte-macrophage colony-stimulating factor by endothelial cells via mRNA stabilization. *Circ. Res.* **1998**, *82*, 794–802. [[CrossRef](#)] [[PubMed](#)]
16. Bergmann, C.E.; Hoefler, I.E.; Meder, B.; Roth, H.; van Royen, N.; Breit, S.M.; Jost, M.M.; Aharinejad, S.; Hartmann, S.; Buschmann, I.R. Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. *J. Leukoc. Biol.* **2006**, *80*, 59–65. [[CrossRef](#)] [[PubMed](#)]
17. Stabile, E.; Burnett, M.S.; Watkins, C.; Kinnaird, T.; Bachis, A.; la Sala, A.; Miller, J.M.; Shou, M.; Epstein, S.E.; Fuchs, S. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. *Circulation* **2003**, *108*, 205–210. [[CrossRef](#)]
18. Van Weel, V.; Toes, R.E.; Seghers, L.; Deckers, M.M.; de Vries, M.R.; Eilers, P.H.; Sipkens, J.; Schepers, A.; Eefting, D.; van Hinsbergh, V.W.; et al. Natural killer cells and CD4+ T-cells modulate collateral artery development. *Arterioscler. Thromb. Vasc. Biol.* **2007**, *27*, 2310–2318. [[CrossRef](#)]
19. Wolf, C.; Cai, W.J.; Vosschulte, R.; Koltai, S.; Mousavipour, D.; Scholz, D.; Afsah-Hedjri, A.; Schaper, W.; Schaper, J. Vascular remodeling and altered protein expression during growth of coronary collateral arteries. *J. Mol. Cell. Cardiol.* **1998**, *30*, 2291–2305. [[CrossRef](#)]
20. Buschmann, I.; Schaper, W. Arteriogenesis Versus Angiogenesis: Two Mechanisms of Vessel Growth. *News Physiol Sci.* **1999**, *14*, 121–125. [[CrossRef](#)]
21. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. *Nat. Med.* **2000**, *6*, 389–395. [[CrossRef](#)] [[PubMed](#)]
22. Schwartz, C.J.; Mitchell, J.R. Cellular infiltration of the human arterial adventitia associated with atheromatous plaques. *Circulation* **1962**, *26*, 73–78. [[CrossRef](#)] [[PubMed](#)]
23. Newman, A.C.; Nakatsu, M.N.; Chou, W.; Gershon, P.D.; Hughes, C.C.W. The requirement for fibroblasts in angiogenesis: Fibroblast-derived matrix proteins are essential for endothelial cell lumen formation. *Mol. Biol. Cell* **2011**, *22*, 3791–3800. [[CrossRef](#)] [[PubMed](#)]
24. Noonan, D.M.; De Lerma Barbaro, A.; Vannini, N.; Mortara, L.; Albin, A. Inflammation, inflammatory cells and angiogenesis: Decisions and indecisions. *Cancer Metastasis Rev.* **2008**, *27*, 31–40. [[CrossRef](#)] [[PubMed](#)]
25. Brennecke, J.; Stark, A.; Russell, R.B.; Cohen, S.M. Principles of microRNA-target recognition. *PLoS Biol.* **2005**, *3*, e85. [[CrossRef](#)]
26. Lewis, B.P.; Shih, I.H.; Jones-Rhoades, M.W.; Bartel, D.P.; Burge, C.B. Prediction of mammalian microRNA targets. *Cell* **2003**, *115*, 787–798. [[CrossRef](#)]
27. Lee, Y.; Jeon, K.; Lee, J.T.; Kim, S.; Kim, V.N. MicroRNA maturation: Stepwise processing and subcellular localization. *EMBO J.* **2002**, *21*, 4663–4670. [[CrossRef](#)]
28. Lee, Y.; Ahn, C.; Han, J.; Choi, H.; Kim, J.; Yim, J.; Lee, J.; Provost, P.; Radmark, O.; Kim, S.; et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature* **2003**, *425*, 415–419. [[CrossRef](#)]
29. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 509–524. [[CrossRef](#)]
30. Kobayashi, H.; Tomari, Y. RISC assembly: Coordination between small RNAs and Argonaute proteins. *Biochim. Biophys. Acta* **2016**, *1859*, 71–81. [[CrossRef](#)]
31. Treiber, T.; Treiber, N.; Plessmann, U.; Harlander, S.; Daiss, J.L.; Eichner, N.; Lehmann, G.; Schall, K.; Urlaub, H.; Meister, G. A Compendium of RNA-Binding Proteins that Regulate MicroRNA Biogenesis. *Mol. Cell* **2017**, *66*, 270. [[CrossRef](#)] [[PubMed](#)]
32. Saito, Y.; Liang, G.; Egger, G.; Friedman, J.M.; Chuang, J.C.; Coetzee, G.A.; Jones, P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. *Cancer Cell* **2006**, *9*, 435–443. [[CrossRef](#)] [[PubMed](#)]
33. Vrba, L.; Munoz-Rodriguez, J.L.; Stampfer, M.R.; Futscher, B.W. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. *PLoS ONE* **2013**, *8*, e54398. [[CrossRef](#)] [[PubMed](#)]
34. Downie Ruiz Velasco, A.; Welten, S.M.J.; Goossens, E.A.C.; Quax, P.H.A.; Rappsilber, J.; Michlewski, G.; Nossent, A.Y. Posttranscriptional Regulation of 14q32 MicroRNAs by the CIRBP and HADHB during Vascular Regeneration after Ischemia. *Mol. Ther. Nucleic Acids* **2019**, *14*, 329–338. [[CrossRef](#)] [[PubMed](#)]

35. Kuehbachner, A.; Urbich, C.; Zeiher, A.M.; Dimmeler, S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. *Circ. Res.* **2007**, *101*, 59–68. [[CrossRef](#)]
36. Suarez, Y.; Fernandez-Hernando, C.; Pober, J.S.; Sessa, W.C. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. *Circ. Res.* **2007**, *100*, 1164–1173. [[CrossRef](#)]
37. Suarez, Y.; Fernandez-Hernando, C.; Yu, J.; Gerber, S.A.; Harrison, K.D.; Pober, J.S.; Iruela-Arispe, M.L.; Merkenschlager, M.; Sessa, W.C. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 14082–14087. [[CrossRef](#)]
38. Kir, D.; Schnettler, E.; Modi, S.; Ramakrishnan, S. Regulation of angiogenesis by microRNAs in cardiovascular diseases. *Angiogenesis* **2018**, *21*, 699–710. [[CrossRef](#)]
39. Lin, X.; Zhan, J.K.; Wang, Y.J.; Tan, P.; Chen, Y.Y.; Deng, H.Q.; Liu, Y.S. Function, Role, and Clinical Application of MicroRNAs in Vascular Aging. *BioMed Res. Int.* **2016**, *2016*, 6021394. [[CrossRef](#)]
40. Sun, L.L.; Li, W.D.; Lei, F.R.; Li, X.Q. The regulatory role of microRNAs in angiogenesis-related diseases. *J. Cell Mol. Med.* **2018**, *22*, 4568–4587. [[CrossRef](#)]
41. Lucas, T.; Bonauer, A.; Dimmeler, S. RNA Therapeutics in Cardiovascular Disease. *Circ. Res.* **2018**, *123*, 205–220. [[CrossRef](#)] [[PubMed](#)]
42. Bonauer, A.; Carmona, G.; Iwasaki, M.; Mione, M.; Koyanagi, M.; Fischer, A.; Burchfield, J.; Fox, H.; Doebele, C.; Ohtani, K.; et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. *Science* **2009**, *324*, 1710–1713. [[CrossRef](#)] [[PubMed](#)]
43. Hinkel, R.; Penzkofer, D.; Zuhlke, S.; Fischer, A.; Husada, W.; Xu, Q.F.; Baloch, E.; van Rooij, E.; Zeiher, A.M.; Kupatt, C.; et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. *Circulation* **2013**, *128*, 1066–1075. [[CrossRef](#)] [[PubMed](#)]
44. Bellera, N.; Barba, I.; Rodriguez-Sinovas, A.; Ferret, E.; Asin, M.A.; Gonzalez-Alujas, M.T.; Perez-Rodon, J.; Esteves, M.; Fonseca, C.; Toran, N.; et al. Single intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling. *J. Am. Heart Assoc.* **2014**, *3*, e000946. [[CrossRef](#)] [[PubMed](#)]
45. Hanna, J.; Hossain, G.S.; Kocerha, J. The Potential for microRNA Therapeutics and Clinical Research. *Front. Genet.* **2019**, *10*, 478. [[CrossRef](#)] [[PubMed](#)]
46. Fish, J.E.; Santoro, M.M.; Morton, S.U.; Yu, S.; Yeh, R.F.; Wythe, J.D.; Ivey, K.N.; Bruneau, B.G.; Stainier, D.Y.; Srivastava, D. miR-126 regulates angiogenic signaling and vascular integrity. *Dev. Cell* **2008**, *15*, 272–284. [[CrossRef](#)] [[PubMed](#)]
47. Wang, S.; Aurora, A.B.; Johnson, B.A.; Qi, X.; McAnally, J.; Hill, J.A.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. *Dev. Cell* **2008**, *15*, 261–271. [[CrossRef](#)]
48. Schober, A.; Nazari-Jahantigh, M.; Wei, Y.; Bidzhekov, K.; Gremse, F.; Grommes, J.; Megens, R.T.; Heyll, K.; Noels, H.; Hristov, M.; et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. *Nat. Med.* **2014**, *20*, 368–376. [[CrossRef](#)]
49. Harris, T.A.; Yamakuchi, M.; Ferlito, M.; Mendell, J.T.; Lowenstein, C.J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 1516–1521. [[CrossRef](#)]
50. Van Solingen, C.; Seghers, L.; Bijkerk, R.; Duijs, J.M.; Roeten, M.K.; van Oeveren-Rietdijk, A.M.; Baelde, H.J.; Monge, M.; Vos, J.B.; de Boer, H.C.; et al. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. *J. Cell Mol. Med.* **2009**, *13*, 1577–1585. [[CrossRef](#)]
51. Katare, R.; Rawal, S.; Munasinghe, P.E.; Tsuchimochi, H.; Inagaki, T.; Fujii, Y.; Dixit, P.; Umetani, K.; Kangawa, K.; Shirai, M.; et al. Ghrelin Promotes Functional Angiogenesis in a Mouse Model of Critical Limb Ischemia Through Activation of Proangiogenic MicroRNAs. *Endocrinology* **2016**, *157*, 432–445. [[CrossRef](#)] [[PubMed](#)]
52. Fichtlscherer, S.; De Rosa, S.; Fox, H.; Schwietz, T.; Fischer, A.; Liebetrau, C.; Weber, M.; Hamm, C.W.; Roxe, T.; Muller-Ardogan, M.; et al. Circulating microRNAs in patients with coronary artery disease. *Circ. Res.* **2010**, *107*, 677–684. [[CrossRef](#)] [[PubMed](#)]
53. Wang, X.; Ling, C.C.; Li, L.; Qin, Y.; Qi, J.; Liu, X.; You, B.; Shi, Y.; Zhang, J.; Jiang, Q.; et al. MicroRNA-10a/10b represses a novel target gene mib1 to regulate angiogenesis. *Cardiovasc. Res.* **2016**, *110*, 140–150. [[CrossRef](#)] [[PubMed](#)]

54. Hergenreider, E.; Heydt, S.; Treguer, K.; Boettger, T.; Horrevoets, A.J.; Zeiher, A.M.; Scheffer, M.P.; Frangakis, A.S.; Yin, X.; Mayr, M.; et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. *Nat. Cell Biol.* **2012**, *14*, 249–256. [[CrossRef](#)] [[PubMed](#)]
55. Fang, Y.; Shi, C.; Manduchi, E.; Civelek, M.; Davies, P.F. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 13450–13455. [[CrossRef](#)]
56. Hassel, D.; Cheng, P.; White, M.P.; Ivey, K.N.; Kroll, J.; Augustin, H.G.; Katus, H.A.; Stainier, D.Y.; Srivastava, D. MicroRNA-10 regulates the angiogenic behavior of zebrafish and human endothelial cells by promoting vascular endothelial growth factor signaling. *Circ. Res.* **2012**, *111*, 1421–1433. [[CrossRef](#)]
57. Liu, L.Z.; Li, C.; Chen, Q.; Jing, Y.; Carpenter, R.; Jiang, Y.; Kung, H.F.; Lai, L.; Jiang, B.H. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1 α expression. *PLoS ONE* **2011**, *6*, e19139. [[CrossRef](#)]
58. Maegdefessel, L.; Azuma, J.; Toh, R.; Deng, A.; Merk, D.R.; Raiesdana, A.; Leeper, N.J.; Raaz, U.; Schoelmerich, A.M.; McConnell, M.V.; et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. *Sci. Transl. Med.* **2012**, *4*, 122ra122. [[CrossRef](#)]
59. Ji, R.; Cheng, Y.; Yue, J.; Yang, J.; Liu, X.; Chen, H.; Dean, D.B.; Zhang, C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. *Circ. Res.* **2007**, *100*, 1579–1588. [[CrossRef](#)]
60. Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature* **2008**, *456*, 980–984. [[CrossRef](#)]
61. Kaluza, D.; Kroll, J.; Gesierich, S.; Manavski, Y.; Boeckel, J.N.; Doebele, C.; Zelent, A.; Rossig, L.; Zeiher, A.M.; Augustin, H.G.; et al. Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells. *Arterioscler. Thromb. Vasc. Biol.* **2013**, *33*, 533–543. [[CrossRef](#)] [[PubMed](#)]
62. Landskroner-Eiger, S.; Qiu, C.; Perrotta, P.; Siragusa, M.; Lee, M.Y.; Ulrich, V.; Luciano, A.K.; Zhuang, Z.W.; Corti, F.; Simons, M.; et al. Endothelial miR-17 approximately 92 cluster negatively regulates arteriogenesis via miRNA-19 repression of WNT signaling. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 12812–12817. [[CrossRef](#)] [[PubMed](#)]
63. Kozomara, A.; Birgaoanu, M.; Griffiths-Jones, S. miRBase: From microRNA sequences to function. *Nucleic Acids Res.* **2019**, *47*, D155–D162. [[CrossRef](#)] [[PubMed](#)]
64. Hoernes, T.P.; Erlacher, M.D. Translating the epitranscriptome. *Wiley Interdiscip. Rev. RNA* **2017**, *8*. [[CrossRef](#)] [[PubMed](#)]
65. Landgraf, P.; Rusu, M.; Sheridan, R.; Sewer, A.; Iovino, N.; Aravin, A.; Pfeffer, S.; Rice, A.; Kamphorst, A.O.; Landthaler, M.; et al. A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell* **2007**, *129*, 1401–1414. [[CrossRef](#)]
66. Blow, M.J.; Grocock, R.J.; van Dongen, S.; Enright, A.J.; Dicks, E.; Futreal, P.A.; Wooster, R.; Stratton, M.R. RNA editing of human microRNAs. *Genome Biol.* **2006**, *7*, R27. [[CrossRef](#)]
67. Cloonan, N.; Wani, S.; Xu, Q.; Gu, J.; Lea, K.; Heater, S.; Barbacioru, C.; Steptoe, A.L.; Martin, H.C.; Nourbakhsh, E.; et al. MicroRNAs and their isomiRs function cooperatively to target common biological pathways. *Genome Biol.* **2011**, *12*, R126. [[CrossRef](#)]
68. Nielsen, C.T.; Goodall, G.J.; Bracken, C.P. IsomiRs—The overlooked repertoire in the dynamic microRNAome. *Trends Genet.* **2012**, *28*, 544–549. [[CrossRef](#)]
69. Llorens, F.; Banez-Coronel, M.; Pantano, L.; del Rio, J.A.; Ferrer, I.; Estivill, X.; Marti, E. A highly expressed miR-101 isomiR is a functional silencing small RNA. *BMC Genom.* **2013**, *14*, 104. [[CrossRef](#)]
70. Loher, P.; Londin, E.R.; Rigoutsos, I. IsomiR expression profiles in human lymphoblastoid cell lines exhibit population and gender dependencies. *Oncotarget* **2014**, *5*, 8790–8802. [[CrossRef](#)]
71. McCall, M.N.; Kim, M.S.; Adil, M.; Patil, A.H.; Lu, Y.; Mitchell, C.J.; Leal-Rojas, P.; Xu, J.; Kumar, M.; Dawson, V.L.; et al. Toward the human cellular microRNAome. *Genome Res.* **2017**, *27*, 1769–1781. [[CrossRef](#)] [[PubMed](#)]
72. Tan, G.C.; Chan, E.; Molnar, A.; Sarkar, R.; Alexieva, D.; Isa, I.M.; Robinson, S.; Zhang, S.; Ellis, P.; Langford, C.F.; et al. 5' isomiR variation is of functional and evolutionary importance. *Nucleic Acids Res.* **2014**, *42*, 9424–9435. [[CrossRef](#)] [[PubMed](#)]

73. Boffill-De Ros, X.; Yang, A.; Gu, S. IsomiRs: Expanding the miRNA repression toolbox beyond the seed. *Biochim. Biophys. Acta Gene Regul. Mech.* **2019**. [[CrossRef](#)] [[PubMed](#)]
74. Telonis, A.G.; Loher, P.; Jing, Y.; Londin, E.; Rigoutsos, I. Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity. *Nucleic Acids Res.* **2015**, *43*, 9158–9175. [[CrossRef](#)] [[PubMed](#)]
75. Burroughs, A.M.; Ando, Y.; de Hoon, M.J.; Tomaru, Y.; Nishibu, T.; Ukekawa, R.; Funakoshi, T.; Kurokawa, T.; Suzuki, H.; Hayashizaki, Y.; et al. A comprehensive survey of 3' animal miRNA modification events and a possible role for 3' adenylation in modulating miRNA targeting effectiveness. *Genome Res.* **2010**, *20*, 1398–1410. [[CrossRef](#)] [[PubMed](#)]
76. Wyman, S.K.; Knouf, E.C.; Parkin, R.K.; Fritz, B.R.; Lin, D.W.; Dennis, L.M.; Krouse, M.A.; Webster, P.J.; Tewari, M. Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. *Genome Res.* **2011**, *21*, 1450–1461. [[CrossRef](#)]
77. Lee, L.W.; Zhang, S.; Etheridge, A.; Ma, L.; Martin, D.; Galas, D.; Wang, K. Complexity of the microRNA repertoire revealed by next-generation sequencing. *RNA* **2010**, *16*, 2170–2180. [[CrossRef](#)]
78. Newman, M.A.; Mani, V.; Hammond, S.M. Deep sequencing of microRNA precursors reveals extensive 3' end modification. *RNA* **2011**, *17*, 1795–1803. [[CrossRef](#)]
79. Mercey, O.; Popa, A.; Cavard, A.; Paquet, A.; Chevalier, B.; Pons, N.; Magnone, V.; Zangari, J.; Brest, P.; Zaragosi, L.E.; et al. Characterizing isomiR variants within the microRNA-34/449 family. *FEBS Lett.* **2017**, *591*, 693–705. [[CrossRef](#)]
80. Karali, M.; Persico, M.; Mutarelli, M.; Carissimo, A.; Pizzo, M.; Singh Marwah, V.; Ambrosio, C.; Pinelli, M.; Carrella, D.; Ferrari, S.; et al. High-resolution analysis of the human retina miRNome reveals isomiR variations and novel microRNAs. *Nucleic Acids Res.* **2016**, *44*, 1525–1540. [[CrossRef](#)]
81. Manzano, M.; Forte, E.; Raja, A.N.; Schipma, M.J.; Gottwein, E. Divergent target recognition by coexpressed 5'-isomiRs of miR-142-3p and selective viral mimicry. *RNA* **2015**, *21*, 1606–1620. [[CrossRef](#)] [[PubMed](#)]
82. Marzi, M.J.; Ghini, F.; Cerruti, B.; de Pretis, S.; Bonetti, P.; Giacomelli, C.; Gorski, M.M.; Kress, T.; Pelizzola, M.; Muller, H.; et al. Degradation dynamics of microRNAs revealed by a novel pulse-chase approach. *Genome Res.* **2016**, *26*, 554–565. [[CrossRef](#)] [[PubMed](#)]
83. Guo, Y.; Liu, J.; Elfenbein, S.J.; Ma, Y.; Zhong, M.; Qiu, C.; Ding, Y.; Lu, J. Characterization of the mammalian miRNA turnover landscape. *Nucleic Acids Res.* **2015**, *43*, 2326–2341. [[CrossRef](#)] [[PubMed](#)]
84. Gutierrez-Vazquez, C.; Enright, A.J.; Rodriguez-Galan, A.; Perez-Garcia, A.; Collier, P.; Jones, M.R.; Benes, V.; Mizgerd, J.P.; Mittelbrunn, M.; Ramiro, A.R.; et al. 3' Uridylation controls mature microRNA turnover during CD4 T-cell activation. *RNA* **2017**, *23*, 882–891. [[CrossRef](#)] [[PubMed](#)]
85. Katoh, T.; Hojo, H.; Suzuki, T. Destabilization of microRNAs in human cells by 3' deadenylation mediated by PARN and CUGBP1. *Nucleic Acids Res.* **2015**, *43*, 7521–7534. [[CrossRef](#)]
86. Katoh, T.; Sakaguchi, Y.; Miyauchi, K.; Suzuki, T.; Kashiwabara, S.; Baba, T.; Suzuki, T. Selective stabilization of mammalian microRNAs by 3' adenylation mediated by the cytoplasmic poly(A) polymerase GLD-2. *Genes Dev.* **2009**, *23*, 433–438. [[CrossRef](#)]
87. Yamane, D.; Selitsky, S.R.; Shimakami, T.; Li, Y.; Zhou, M.; Honda, M.; Sethupathy, P.; Lemon, S.M. Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3 variants. *Nucleic Acids Res.* **2017**, *45*, 4743–4755. [[CrossRef](#)]
88. Yu, F.; Pillman, K.A.; Neilsen, C.T.; Toubia, J.; Lawrence, D.M.; Tsykin, A.; Gantier, M.P.; Callen, D.F.; Goodall, G.J.; Bracken, C.P. Naturally existing isoforms of miR-222 have distinct functions. *Nucleic Acids Res.* **2017**, *45*, 11371–11385. [[CrossRef](#)]
89. Voellenkle, C.; Rooij, J.; Guffanti, A.; Brini, E.; Fasanaro, P.; Isaia, E.; Croft, L.; David, M.; Capogrossi, M.C.; Moles, A.; et al. Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs. *RNA* **2012**, *18*, 472–484. [[CrossRef](#)]
90. Chistiakov, D.A.; Orekhov, A.N.; Bobryshev, Y.V. The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. *J. Mol. Cell. Cardiol.* **2016**, *97*, 47–55. [[CrossRef](#)]
91. Guduric-Fuchs, J.; O'Connor, A.; Cullen, A.; Harwood, L.; Medina, R.J.; O'Neill, C.L.; Stitt, A.W.; Curtis, T.M.; Simpson, D.A. Deep sequencing reveals predominant expression of miR-21 amongst the small non-coding RNAs in retinal microvascular endothelial cells. *J. Cell. Biochem.* **2012**, *113*, 2098–2111. [[CrossRef](#)] [[PubMed](#)]

92. Fernandez-Valverde, S.L.; Taft, R.J.; Mattick, J.S. Dynamic isomiR regulation in Drosophila development. *RNA* **2010**, *16*, 1881–1888. [[CrossRef](#)] [[PubMed](#)]
93. Schirmer, S.H.; Fledderus, J.O.; Bot, P.T.; Moerland, P.D.; Hoefler, I.E.; Baan, J., Jr.; Henriques, J.P.; van der Schaaf, R.J.; Vis, M.M.; Horrevoets, A.J.; et al. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. *Circ. Res.* **2008**, *102*, 1286–1294. [[CrossRef](#)] [[PubMed](#)]
94. Yildirim, C.; Nieuwenhuis, S.; Teunissen, P.F.; Horrevoets, A.J.; van Royen, N.; van der Pouw Kraan, T.C. Interferon-Beta, a Decisive Factor in Angiogenesis and Arteriogenesis. *J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res.* **2015**, *35*, 411–420. [[CrossRef](#)] [[PubMed](#)]
95. Schirmer, S.H.; Bot, P.T.; Fledderus, J.O.; van der Laan, A.M.; Volger, O.L.; Laufs, U.; Bohm, M.; de Vries, C.J.; Horrevoets, A.J.; Piek, J.J.; et al. Blocking interferon-beta stimulates vascular smooth muscle cell proliferation and arteriogenesis. *J. Biol. Chem.* **2010**, *285*, 34677–34685. [[CrossRef](#)] [[PubMed](#)]
96. Nejad, C.; Pillman, K.A.; Siddle, K.J.; Pepin, G.; Anko, M.L.; McCoy, C.E.; Beilharz, T.H.; Quintana-Murci, L.; Goodall, G.J.; Bracken, C.P.; et al. miR-222 isoforms are differentially regulated by type-I interferon. *RNA* **2018**, *24*, 332–341. [[CrossRef](#)] [[PubMed](#)]
97. Poliseno, L.; Tuccoli, A.; Mariani, L.; Evangelista, M.; Citti, L.; Woods, K.; Mercatanti, A.; Hammond, S.; Rainaldi, G. MicroRNAs modulate the angiogenic properties of HUVECs. *Blood* **2006**, *108*, 3068–3071. [[CrossRef](#)]
98. Dentelli, P.; Rosso, A.; Orso, F.; Olgasi, C.; Taverna, D.; Brizzi, M.F. microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. *Arterioscler. Thromb. Vasc. Biol.* **2010**, *30*, 1562–1568. [[CrossRef](#)]
99. Van der Kwast, R.; Woudenberg, T.; Quax, P.H.A.; Nossent, A.Y. MicroRNA-411 and Its 5'-IsomiR Have Distinct Targets and Functions and Are Differentially Regulated in the Vasculature under Ischemia. *Mol. Ther. J. Am. Soc. Gene Ther.* **2019**. [[CrossRef](#)]
100. Wagner, R.W.; Smith, J.E.; Cooperman, B.S.; Nishikura, K. A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and *Xenopus* eggs. *Proc. Natl. Acad. Sci. USA* **1989**, *86*, 2647–2651. [[CrossRef](#)]
101. Gommans, W.M. A-to-I editing of microRNAs: Regulating the regulators? *Semin. Cell Dev. Biol.* **2012**, *23*, 251–257. [[CrossRef](#)] [[PubMed](#)]
102. Kume, H.; Hino, K.; Galipon, J.; Ui-Tei, K. A-to-I editing in the miRNA seed region regulates target mRNA selection and silencing efficiency. *Nucleic Acids Res.* **2014**, *42*, 10050–10060. [[CrossRef](#)] [[PubMed](#)]
103. Savva, Y.A.; Rieder, L.E.; Reenan, R.A. The ADAR protein family. *Genome Biol.* **2012**, *13*, 252. [[CrossRef](#)] [[PubMed](#)]
104. Nishikura, K. A-to-I editing of coding and non-coding RNAs by ADARs. *Nat. Rev. Mol. Cell Biol.* **2016**, *17*, 83–96. [[CrossRef](#)]
105. Mallela, A.; Nishikura, K. A-to-I editing of protein coding and noncoding RNAs. *Crit. Rev. Biochem. Mol. Biol.* **2012**, *47*, 493–501. [[CrossRef](#)]
106. Nigita, G.; Veneziano, D.; Ferro, A. A-to-I RNA Editing: Current Knowledge Sources and Computational Approaches with Special Emphasis on Non-Coding RNA Molecules. *Front. Bioeng. Biotechnol.* **2015**, *3*. [[CrossRef](#)]
107. Wang, Q.; Khillan, J.; Gadue, P.; Nishikura, K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. *Science* **2000**, *290*, 1765–1768. [[CrossRef](#)]
108. Higuchi, M.; Maas, S.; Single, F.N.; Hartner, J.; Rozov, A.; Burnashev, N.; Feldmeyer, D.; Sprengel, R.; Seeburg, P.H. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. *Nature* **2000**, *406*, 78–81. [[CrossRef](#)]
109. Brusa, R.; Zimmermann, F.; Koh, D.S.; Feldmeyer, D.; Gass, P.; Seeburg, P.H.; Sprengel, R. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. *Science* **1995**, *270*, 1677–1680. [[CrossRef](#)]
110. Hong, H.; Lin, J.; Chen, L. Regulatory factors governing adenosine-to-inosine (A-to-I) RNA editing. *Biosci Rep.* **2015**, *35*. [[CrossRef](#)]
111. Lai, F.; Chen, C.X.; Lee, V.M.; Nishikura, K. Dramatic increase of the RNA editing for glutamate receptor subunits during terminal differentiation of clonal human neurons. *J. Neurochem.* **1997**, *69*, 43–52. [[CrossRef](#)] [[PubMed](#)]

112. Liu, Y.; Emeson, R.B.; Samuel, C.E. Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1. *J. Biol. Chem.* **1999**, *274*, 18351–18358. [[CrossRef](#)] [[PubMed](#)]
113. Yang, W.; Chendrimada, T.P.; Wang, Q.; Higuchi, M.; Seeburg, P.H.; Shiekhhattar, R.; Nishikura, K. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. *Nat. Struct. Mol. Biol.* **2006**, *13*, 13–21. [[CrossRef](#)] [[PubMed](#)]
114. Kawahara, Y.; Zinshteyn, B.; Chendrimada, T.P.; Shiekhhattar, R.; Nishikura, K. RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer-TRBP complex. *EMBO Rep.* **2007**, *8*, 763–769. [[CrossRef](#)]
115. Kawahara, Y.; Megraw, M.; Kreider, E.; Iizasa, H.; Valente, L.; Hatzigeorgiou, A.G.; Nishikura, K. Frequency and fate of microRNA editing in human brain. *Nucleic Acids Res.* **2008**, *36*, 5270–5280. [[CrossRef](#)]
116. Kawahara, Y.; Zinshteyn, B.; Sethupathy, P.; Iizasa, H.; Hatzigeorgiou, A.G.; Nishikura, K. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. *Science* **2007**, *315*, 1137–1140. [[CrossRef](#)]
117. Li, L.; Song, Y.; Shi, X.; Liu, J.; Xiong, S.; Chen, W.; Fu, Q.; Huang, Z.; Gu, N.; Zhang, R. The landscape of miRNA editing in animals and its impact on miRNA biogenesis and targeting. *Genome Res.* **2018**, *28*, 132–143. [[CrossRef](#)]
118. Vitsios, D.M.; Davis, M.P.; van Dongen, S.; Enright, A.J. Large-scale analysis of microRNA expression, epi-transcriptomic features and biogenesis. *Nucleic Acids Res.* **2016**. [[CrossRef](#)]
119. Wang, Y.; Liang, H. When MicroRNAs Meet RNA Editing in Cancer: A Nucleotide Change Can Make a Difference. *Bioessays News Rev. Mol. Cell. Dev. Biol.* **2018**, *40*. [[CrossRef](#)]
120. Wang, Y.; Xu, X.; Yu, S.; Jeong, K.J.; Zhou, Z.; Han, L.; Tsang, Y.H.; Li, J.; Chen, H.; Mangala, L.S.; et al. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. *Genome Res.* **2017**, *27*, 1112–1125. [[CrossRef](#)]
121. Cho, C.J.; Myung, S.J.; Chang, S. ADAR1 and MicroRNA.; A Hidden Crosstalk in Cancer. *Int. J. Mol. Sci.* **2017**, *18*, 799. [[CrossRef](#)] [[PubMed](#)]
122. Shoshan, E.; Mobley, A.K.; Braeuer, R.R.; Kamiya, T.; Huang, L.; Vasquez, M.E.; Salameh, A.; Lee, H.J.; Kim, S.J.; Ivan, C.; et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. *Nat. Cell Biol.* **2015**, *17*, 311–321. [[CrossRef](#)] [[PubMed](#)]
123. Van der Kwast, R.V.C.T.; van Ingen, E.; Parma, L.; Peters, H.A.B.; Quax, P.H.A.; Nossent, A.Y. Adenosine-to-Inosine Editing of MicroRNA-487b Alters Target Gene Selection After Ischemia and Promotes Neovascularization. *Circ. Res.* **2018**, *122*, 444–456. [[CrossRef](#)] [[PubMed](#)]
124. Dominissini, D.; Moshitch-Moshkovitz, S.; Schwartz, S.; Salmon-Divon, M.; Ungar, L.; Osenberg, S.; Cesarkas, K.; Jacob-Hirsch, J.; Amariglio, N.; Kupiec, M.; et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. *Nature* **2012**, *485*, 201–206. [[CrossRef](#)]
125. Meyer, K.D.; Saletore, Y.; Zumbo, P.; Elemento, O.; Mason, C.E.; Jaffrey, S.R. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell* **2012**, *149*, 1635–1646. [[CrossRef](#)]
126. Wang, P.; Doxtader, K.A.; Nam, Y. Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. *Mol. Cell* **2016**, *63*, 306–317. [[CrossRef](#)]
127. Yang, Y.; Hsu, P.J.; Chen, Y.S.; Yang, Y.G. Dynamic transcriptomic m(6)A decoration: Writers, erasers, readers and functions in RNA metabolism. *Cell Res.* **2018**, *28*, 616–624. [[CrossRef](#)]
128. Schwartz, S.; Mumbach, M.R.; Jovanovic, M.; Wang, T.; Maciag, K.; Bushkin, G.G.; Mertins, P.; Ter-Ovanesyan, D.; Habib, N.; Cacchiarelli, D.; et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. *Cell Rep.* **2014**, *8*, 284–296. [[CrossRef](#)]
129. Zheng, G.; Dahl, J.A.; Niu, Y.; Fedorcsak, P.; Huang, C.M.; Li, C.J.; Vagbo, C.B.; Shi, Y.; Wang, W.L.; Song, S.H.; et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. *Mol. Cell* **2013**, *49*, 18–29. [[CrossRef](#)]
130. Jia, G.; Fu, Y.; Zhao, X.; Dai, Q.; Zheng, G.; Yang, Y.; Yi, C.; Lindahl, T.; Pan, T.; Yang, Y.G.; et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat. Chem. Biol.* **2011**, *7*, 885–887. [[CrossRef](#)]
131. Roundtree, I.A.; Evans, M.E.; Pan, T.; He, C. Dynamic RNA Modifications in Gene Expression Regulation. *Cell* **2017**, *169*, 1187–1200. [[CrossRef](#)] [[PubMed](#)]
132. Zhao, B.S.; Roundtree, I.A.; He, C. Post-transcriptional gene regulation by mRNA modifications. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 31–42. [[CrossRef](#)] [[PubMed](#)]

133. Nachtergaele, S.; He, C. The emerging biology of RNA post-transcriptional modifications. *RNA Biol.* **2017**, *14*, 156–163. [[CrossRef](#)] [[PubMed](#)]
134. Yoon, K.J.; Ringeling, F.R.; Vissers, C.; Jacob, F.; Pokrass, M.; Jimenez-Cyrus, D.; Su, Y.; Kim, N.S.; Zhu, Y.; Zheng, L.; et al. Temporal Control of Mammalian Cortical Neurogenesis by m(6)A Methylation. *Cell* **2017**, *171*, 877–889. [[CrossRef](#)] [[PubMed](#)]
135. Wang, Y.; Li, Y.; Toth, J.I.; Petroski, M.D.; Zhang, Z.; Zhao, J.C. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. *Nat. Cell Biol.* **2014**, *16*, 191–198. [[CrossRef](#)] [[PubMed](#)]
136. Horiuchi, K.; Umetani, M.; Minami, T.; Okayama, H.; Takada, S.; Yamamoto, M.; Aburatani, H.; Reid, P.C.; Housman, D.E.; Hamakubo, T.; et al. Wilms' tumor 1-associating protein regulates G2/M transition through stabilization of cyclin A2 mRNA. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 17278–17283. [[CrossRef](#)]
137. Liu, N.; Zhou, K.I.; Parisien, M.; Dai, Q.; Diatchenko, L.; Pan, T. N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. *Nucleic Acids Res.* **2017**, *45*, 6051–6063. [[CrossRef](#)]
138. Liu, N.; Dai, Q.; Zheng, G.; He, C.; Parisien, M.; Pan, T. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. *Nature* **2015**, *518*, 560–564. [[CrossRef](#)]
139. Huang, H.; Weng, H.; Sun, W.; Qin, X.; Shi, H.; Wu, H.; Zhao, B.S.; Mesquita, A.; Liu, C.; Yuan, C.L.; et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. *Nat. Cell Biol.* **2018**, *20*, 285–295. [[CrossRef](#)]
140. Wang, X.; Zhao, B.S.; Roundtree, I.A.; Lu, Z.; Han, D.; Ma, H.; Weng, X.; Chen, K.; Shi, H.; He, C. N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. *Cell* **2015**, *161*, 1388–1399. [[CrossRef](#)]
141. Wang, X.; Lu, Z.; Gomez, A.; Hon, G.C.; Yue, Y.; Han, D.; Fu, Y.; Parisien, M.; Dai, Q.; Jia, G.; et al. N6-methyladenosine-dependent regulation of messenger RNA stability. *Nature* **2014**, *505*, 117–120. [[CrossRef](#)] [[PubMed](#)]
142. Alarcon, C.R.; Goodarzi, H.; Lee, H.; Liu, X.; Tavazoie, S.; Tavazoie, S.F. HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events. *Cell* **2015**, *162*, 1299–1308. [[CrossRef](#)] [[PubMed](#)]
143. Alarcon, C.R.; Lee, H.; Goodarzi, H.; Halberg, N.; Tavazoie, S.F. N6-methyladenosine marks primary microRNAs for processing. *Nature* **2015**, *519*, 482–485. [[CrossRef](#)] [[PubMed](#)]
144. Dai, Q.; Fong, R.; Saikia, M.; Stephenson, D.; Yu, Y.T.; Pan, T.; Piccirilli, J.A. Identification of recognition residues for ligation-based detection and quantitation of pseudouridine and N6-methyladenosine. *Nucleic Acids Res.* **2007**, *35*, 6322–6329. [[CrossRef](#)]
145. Konno, M.; Koseki, J.; Asai, A.; Yamagata, A.; Shimamura, T.; Motooka, D.; Okuzaki, D.; Kawamoto, K.; Mizushima, T.; Eguchi, H.; et al. Distinct methylation levels of mature microRNAs in gastrointestinal cancers. *Nat. Commun.* **2019**, *10*, 3888. [[CrossRef](#)]
146. Muller, S.; Glass, M.; Singh, A.K.; Haase, J.; Bley, N.; Fuchs, T.; Lederer, M.; Dahl, A.; Huang, H.; Chen, J.; et al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. *Nucleic Acids Res.* **2019**, *47*, 375–390. [[CrossRef](#)]
147. Dorn, L.E.; Lasman, L.; Chen, J.; Xu, X.; Hund, T.J.; Medvedovic, M.; Hanna, J.H.; van Berlo, J.H.; Accornero, F. The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy. *Circulation* **2019**, *139*, 533–545. [[CrossRef](#)]
148. Mathiyalagan, P.; Adamiak, M.; Mayourian, J.; Sassi, Y.; Liang, Y.; Agarwal, N.; Jha, D.; Zhang, S.; Kohlbrenner, E.; Chepurko, E.; et al. FTO-Dependent N(6)-Methyladenosine Regulates Cardiac Function During Remodeling and Repair. *Circulation* **2019**, *139*, 518–532. [[CrossRef](#)]
149. Ma, J.Z.; Yang, F.; Zhou, C.C.; Liu, F.; Yuan, J.H.; Wang, F.; Wang, T.T.; Xu, Q.G.; Zhou, W.P.; Sun, S.H. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6)-methyladenosine-dependent primary MicroRNA processing. *Hepatology* **2017**, *65*, 529–543. [[CrossRef](#)]
150. Han, J.; Wang, J.Z.; Yang, X.; Yu, H.; Zhou, R.; Lu, H.C.; Yuan, W.B.; Lu, J.C.; Zhou, Z.J.; Lu, Q.; et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. *Mol. Cancer* **2019**, *18*, 110. [[CrossRef](#)]
151. Cech, T.R.; Steitz, J.A. The noncoding RNA revolution—trashing old rules to forge new ones. *Cell* **2014**, *157*, 77–94. [[CrossRef](#)] [[PubMed](#)]
152. Kim, Y.K.; Heo, I.; Kim, V.N. Modifications of small RNAs and their associated proteins. *Cell* **2010**, *143*, 703–709. [[CrossRef](#)] [[PubMed](#)]

153. Zhang, X.; Cozen, A.E.; Liu, Y.; Chen, Q.; Lowe, T.M. Small RNA Modifications: Integral to Function and Disease. *Trends Mol. Med.* **2016**, *22*, 1025–1034. [[CrossRef](#)] [[PubMed](#)]
154. Lan, M.D.; Xiong, J.; You, X.J.; Weng, X.C.; Zhou, X.; Yuan, B.F.; Feng, Y.Q. Existence of Diverse Modifications in Small-RNA Species Composed of 16–28 Nucleotides. *Chem. Eur. J.* **2018**, *24*, 9949–9956. [[CrossRef](#)] [[PubMed](#)]
155. Charette, M.; Gray, M.W. Pseudouridine in RNA: What, where, how, and why. *Subcell. Life* **2000**, *49*, 341–351. [[CrossRef](#)] [[PubMed](#)]
156. Karijolich, J.; Yi, C.; Yu, Y.T. Transcriptome-wide dynamics of RNA pseudouridylation. *Nat. Rev. Mol. Cell Biol.* **2015**, *16*, 581–585. [[CrossRef](#)]
157. Schwartz, S.; Bernstein, D.A.; Mumbach, M.R.; Jovanovic, M.; Herbst, R.H.; Leon-Ricardo, B.X.; Engreitz, J.M.; Guttman, M.; Satija, R.; Lander, E.S.; et al. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. *Cell* **2014**, *159*, 148–162. [[CrossRef](#)]
158. Arnez, J.G.; Steitz, T.A. Crystal structure of unmodified tRNA(Gln) complexed with glutamyl-tRNA synthetase and ATP suggests a possible role for pseudo-uridines in stabilization of RNA structure. *Biochemistry* **1994**, *33*, 7560–7567. [[CrossRef](#)]
159. Cohn, W.E. Pseudouridine, a carbon-carbon linked ribonucleoside in ribonucleic acids: Isolation, structure, and chemical characteristics. *J. Biol. Chem.* **1960**, *235*, 1488–1498.
160. Carlile, T.M.; Rojas-Duran, M.F.; Zinshteyn, B.; Shin, H.; Bartoli, K.M.; Gilbert, W.V. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. *Nature* **2014**, *515*, 143–146. [[CrossRef](#)]
161. Ayadi, L.; Galvanin, A.; Pichot, F.; Marchand, V.; Motorin, Y. RNA ribose methylation (2'-O-methylation): Occurrence, biosynthesis and biological functions. *Biochim. Biophys. Acta Gene Regul. Mech.* **2018**. [[CrossRef](#)] [[PubMed](#)]
162. Dimitrova, D.G.; Teyssset, L.; Carre, C. RNA 2'-O-Methylation (Nm) Modification in Human Diseases. *Genes* **2019**, *10*, 117. [[CrossRef](#)] [[PubMed](#)]
163. Bachellerie, J.P.; Cavaille, J.; Huttenhofer, A. The expanding snoRNA world. *Biochimie* **2002**, *84*, 775–790. [[CrossRef](#)]
164. Cavaille, J.; Buiting, K.; Kiefmann, M.; Lalande, M.; Brannan, C.I.; Horsthemke, B.; Bachellerie, J.P.; Brosius, J.; Huttenhofer, A. Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 14311–14316. [[CrossRef](#)]
165. Vitali, P.; Basyuk, E.; Le, M.E.; Bertrand, E.; Muscatelli, F.; Cavaille, J.; Huttenhofer, A. ADAR2-mediated editing of RNA substrates in the nucleolus is inhibited by C/D small nucleolar RNAs. *J. Cell Biol.* **2005**, *169*, 745–753. [[CrossRef](#)]
166. Yi-Brunozzi, H.Y.; Easterwood, L.M.; Kamilar, G.M.; Beal, P.A. Synthetic substrate analogs for the RNA-editing adenosine deaminase ADAR-2. *Nucleic Acids Res.* **1999**, *27*, 2912–2917. [[CrossRef](#)]
167. Mizrahi, R.A.; Phelps, K.J.; Ching, A.Y.; Beal, P.A. Nucleoside analog studies indicate mechanistic differences between RNA-editing adenosine deaminases. *Nucleic Acids Res.* **2012**, *40*, 9825–9835. [[CrossRef](#)]
168. Inoue, H.; Hayase, Y.; Imura, A.; Iwai, S.; Miura, K.; Ohtsuka, E. Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides. *Nucleic Acids Res.* **1987**, *15*, 6131–6148. [[CrossRef](#)]
169. Majlessi, M.; Nelson, N.C.; Becker, M.M. Advantages of 2'-O-methyl oligoribonucleotide probes for detecting RNA targets. *Nucleic Acids Res.* **1998**, *26*, 2224–2229. [[CrossRef](#)]
170. Tsourkas, A.; Behlke, M.A.; Bao, G. Hybridization of 2'-O-methyl and 2'-deoxy molecular beacons to RNA and DNA targets. *Nucleic Acids Res.* **2002**, *30*, 5168–5174. [[CrossRef](#)]
171. Yu, B.; Yang, Z.; Li, J.; Minakhina, S.; Yang, M.; Padgett, R.W.; Steward, R.; Chen, X. Methylation as a crucial step in plant microRNA biogenesis. *Science* **2005**, *307*, 932–935. [[CrossRef](#)] [[PubMed](#)]
172. Dominissini, D.; Nachtergaele, S.; Moshitch-Moshkovitz, S.; Peer, E.; Kol, N.; Ben-Haim, M.S.; Dai, Q.; Di Segni, A.; Salmon-Divon, M.; Clark, W.C.; et al. The dynamic N1-methyladenosine methylome in eukaryotic messenger RNA. *Nature* **2016**, *530*, 441–446. [[CrossRef](#)] [[PubMed](#)]
173. Li, X.; Xiong, X.; Wang, K.; Wang, L.; Shu, X.; Ma, S.; Yi, C. Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome. *Nat. Chem. Biol.* **2016**, *12*, 311–316. [[CrossRef](#)] [[PubMed](#)]
174. Zhang, C.; Jia, G. Reversible RNA Modification N(1)-methyladenosine (m(1)A) in mRNA and tRNA. *Genom. Proteom. Bioinform.* **2018**, *16*, 155–161. [[CrossRef](#)]
175. Liu, F.; Clark, W.; Luo, G.; Wang, X.; Fu, Y.; Wei, J.; Wang, X.; Hao, Z.; Dai, Q.; Zheng, G.; et al. ALKBH1-Mediated tRNA Demethylation Regulates Translation. *Cell* **2016**, *167*, 816–828. [[CrossRef](#)]

176. Zhou, H.; Kimsey, I.J.; Nikolova, E.N.; Sathyamoorthy, B.; Grazioli, G.; McSally, J.; Bai, T.; Wunderlich, C.H.; Kreutz, C.; Andricioaei, I.; et al. m(1)A and m(1)G disrupt A-RNA structure through the intrinsic instability of Hoogsteen base pairs. *Nat. Struct. Mol. Biol.* **2016**, *23*, 803–810. [[CrossRef](#)]
177. Squires, J.E.; Patel, H.R.; Nousch, M.; Sibbritt, T.; Humphreys, D.T.; Parker, B.J.; Suter, C.M.; Preiss, T. Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. *Nucleic Acids Res.* **2012**, *40*, 5023–5033. [[CrossRef](#)]
178. Van Haute, L.; Dietmann, S.; Kremer, L.; Hussain, S.; Pearce, S.F.; Powell, C.A.; Rorbach, J.; Lantaff, R.; Blanco, S.; Sauer, S.; et al. Deficient methylation and formylation of mt-tRNA(Met) wobble cytosine in a patient carrying mutations in NSUN3. *Nat. Commun.* **2016**, *7*, 12039. [[CrossRef](#)]
179. Nakano, S.; Suzuki, T.; Kawarada, L.; Iwata, H.; Asano, K.; Suzuki, T. NSUN3 methylase initiates 5-formylcytidine biogenesis in human mitochondrial tRNA(Met). *Nat. Chem. Biol.* **2016**, *12*, 546–551. [[CrossRef](#)]
180. Goll, M.G.; Kirpekar, F.; Maggert, K.A.; Yoder, J.A.; Hsieh, C.L.; Zhang, X.; Golic, K.G.; Jacobsen, S.E.; Bestor, T.H. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. *Science* **2006**, *311*, 395–398. [[CrossRef](#)]
181. Trixl, L.; Lusser, A. The dynamic RNA modification 5-methylcytosine and its emerging role as an epitranscriptomic mark. *Wiley Interdiscip. Rev. RNA* **2019**, *10*, e1510. [[CrossRef](#)] [[PubMed](#)]
182. Hussain, S.; Sajini, A.A.; Blanco, S.; Dietmann, S.; Lombard, P.; Sugimoto, Y.; Paramor, M.; Gleeson, J.G.; Odom, D.T.; Ule, J.; et al. NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing into regulatory small RNAs. *Cell Rep.* **2013**, *4*, 255–261. [[CrossRef](#)] [[PubMed](#)]
183. Khoddami, V.; Cairns, B.R. Identification of direct targets and modified bases of RNA cytosine methyltransferases. *Nat. Biotechnol.* **2013**, *31*, 458–464. [[CrossRef](#)] [[PubMed](#)]
184. Jurkowski, T.P.; Meusburger, M.; Phalke, S.; Helm, M.; Nellen, W.; Reuter, G.; Jeltsch, A. Human DNMT2 methylates tRNA(Asp) molecules using a DNA methyltransferase-like catalytic mechanism. *RNA* **2008**, *14*, 1663–1670. [[CrossRef](#)] [[PubMed](#)]
185. Schaefer, M.; Pollex, T.; Hanna, K.; Tuorto, F.; Meusburger, M.; Helm, M.; Lyko, F. RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. *Genes Dev.* **2010**, *24*, 1590–1595. [[CrossRef](#)]
186. Aguiló, F.; Li, S.; Balasubramanian, N.; Sancho, A.; Benko, S.; Zhang, F.; Vashisht, A.; Rengasamy, M.; Andino, B.; Chen, C.H.; et al. Deposition of 5-Methylcytosine on Enhancer RNAs Enables the Coactivator Function of PGC-1alpha. *Cell Rep.* **2016**, *14*, 479–492. [[CrossRef](#)]
187. Sergiev, P.V.; Bogdanov, A.A.; Dontsova, O.A. Ribosomal RNA guanine-(N2)-methyltransferases and their targets. *Nucleic Acids Res.* **2007**, *35*, 2295–2301. [[CrossRef](#)]
188. Chen, W.; Song, X.; Lv, H.; Lin, H. iRNA-m2G: Identifying N(2)-methylguanosine Sites Based on Sequence-Derived Information. *Mol. Ther. Nucleic Acids* **2019**, *18*, 253–258. [[CrossRef](#)]
189. Bavi, R.S.; Kamble, A.D.; Kumbhar, N.M.; Kumbhar, B.V.; Sonawane, K.D. Conformational preferences of modified nucleoside N(2)-methylguanosine (m(2)G) and its derivative N(2), N(2)-dimethylguanosine (m(2)(2)G) occur at 26th position (hinge region) in tRNA. *Cell Biochem. Biophys.* **2011**, *61*, 507–521. [[CrossRef](#)]
190. Bavi, R.S.; Sambhare, S.B.; Sonawane, K.D. MD simulation studies to investigate iso-energetic conformational behaviour of modified nucleosides m(2)G and m(2) 2G present in tRNA. *Comput. Struct. Biotechnol. J.* **2013**, *5*, e201302015. [[CrossRef](#)]
191. Pinto, Y.; Buchumenski, I.; Levanon, E.Y.; Eisenberg, E. Human cancer tissues exhibit reduced A-to-I editing of miRNAs coupled with elevated editing of their targets. *Nucleic Acids Res.* **2018**, *46*, 71–82. [[CrossRef](#)] [[PubMed](#)]
192. Esteller, M.; Pandolfi, P.P. The Epitranscriptome of Noncoding RNAs in Cancer. *Cancer Discov.* **2017**, *7*, 359–368. [[CrossRef](#)] [[PubMed](#)]
193. Meyer, K.D.; Patil, D.P.; Zhou, J.; Zinoviev, A.; Skabkin, M.A.; Elemento, O.; Pestova, T.V.; Qian, S.B.; Jaffrey, S.R. 5' UTR m(6)A Promotes Cap-Independent Translation. *Cell* **2015**, *163*, 999–1010. [[CrossRef](#)] [[PubMed](#)]
194. Xiang, Y.; Laurent, B.; Hsu, C.H.; Nachtergaele, S.; Lu, Z.; Sheng, W.; Xu, C.; Chen, H.; Ouyang, J.; Wang, S.; et al. RNA m(6)A methylation regulates the ultraviolet-induced DNA damage response. *Nature* **2017**, *543*, 573–576. [[CrossRef](#)]
195. Zhou, J.; Wan, J.; Gao, X.; Zhang, X.; Jaffrey, S.R.; Qian, S.B. Dynamic m(6)A mRNA methylation directs translational control of heat shock response. *Nature* **2015**, *526*, 591–594. [[CrossRef](#)]

196. Blanco, S.; Bandiera, R.; Popis, M.; Hussain, S.; Lombard, P.; Aleksic, J.; Sajini, A.; Tanna, H.; Cortes-Garrido, R.; Gkatza, N.; et al. Stem cell function and stress response are controlled by protein synthesis. *Nature* **2016**, *534*, 335–340. [[CrossRef](#)]
197. Blanco, S.; Dietmann, S.; Flores, J.V.; Hussain, S.; Kutter, C.; Humphreys, P.; Lukk, M.; Lombard, P.; Treps, L.; Popis, M.; et al. Aberrant methylation of tRNAs links cellular stress to neuro-developmental disorders. *EMBO J.* **2014**, *33*, 2020–2039. [[CrossRef](#)]
198. Krogh, N.; Jansson, M.D.; Hafner, S.J.; Tehler, D.; Birkedal, U.; Christensen-Dalsgaard, M.; Lund, A.H.; Nielsen, H. Profiling of 2'-O-Me in human rRNA reveals a subset of fractionally modified positions and provides evidence for ribosome heterogeneity. *Nucleic Acids Res.* **2016**, *44*, 7884–7895. [[CrossRef](#)]
199. Marcel, V.; Ghayad, S.E.; Belin, S.; Therizols, G.; Morel, A.P.; Solano-Gonzalez, E.; Vendrell, J.A.; Hacot, S.; Mertani, H.C.; Albaret, M.A.; et al. p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. *Cancer Cell* **2013**, *24*, 318–330. [[CrossRef](#)]
200. Gatsiou, A.; Stellos, K. Dawn of Epitranscriptomic Medicine. *Circ. Genom. Precis. Med.* **2018**, *11*, e001927. [[CrossRef](#)]
201. Stellos, K.; Gatsiou, A.; Stamatelopoulos, K.; Perisic Matic, L.; John, D.; Lunella, F.F.; Jae, N.; Rossbach, O.; Amrhein, C.; Sigala, F.; et al. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. *Nat. Med.* **2016**, *22*, 1140–1150. [[CrossRef](#)] [[PubMed](#)]
202. Veliz, E.A.; Easterwood, L.M.; Beal, P.A. Substrate analogues for an RNA-editing adenosine deaminase: Mechanistic investigation and inhibitor design. *J. Am. Chem. Soc.* **2003**, *125*, 10867–10876. [[CrossRef](#)] [[PubMed](#)]
203. Xiang, J.F.; Yang, Q.; Liu, C.X.; Wu, M.; Chen, L.L.; Yang, L. N(6)-Methyladenosines Modulate A-to-I RNA Editing. *Mol. Cell* **2018**, *69*, 126–135.e126. [[CrossRef](#)] [[PubMed](#)]
204. Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. *Nat. Rev. Drug Discov.* **2017**, *16*, 203–222. [[CrossRef](#)]
205. Telonis, A.G.; Magee, R.; Loher, P.; Chervoneva, I.; Londin, E.; Rigoutsos, I. Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. *Nucleic Acids Res.* **2017**, *45*, 2973–2985. [[CrossRef](#)]
206. Schaefer, M.; Kapoor, U.; Jantsch, M.F. Understanding RNA modifications: The promises and technological bottlenecks of the 'epitranscriptome'. *Open Biol.* **2017**, *7*, 170077. [[CrossRef](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).